<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="65299">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01698138</url>
  </required_header>
  <id_info>
    <org_study_id>2012/1151</org_study_id>
    <nct_id>NCT01698138</nct_id>
  </id_info>
  <brief_title>Prevention of Bladder Dysfunction in Acute Spinal Cord Injury</brief_title>
  <acronym>BOT-SCI</acronym>
  <official_title>Prevention of Bladder Dysfunction in Acute Spinal Cord Injury. A Double-blind, Randomized, Placebo-controlled Study to Explore the Effect of Early Treatment With Onabotulinumtoxin A on Development of Detrusor Overactivity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sunnaas Rehabilitation Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <authority>Norway: Regional Committee for Medical and Health Research Ethic (REK), South East</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a double blind, randomized, placebo controlled trial to explore the effect of
      early treatment with Onabotulinumtoxin A in patients with acute complete motor spinal cord
      injury (SCI) on the development of neurogenic detrusor overactivity (NDO). A total of 20
      patients will be randomized to intra-detrusor injection of 300 U Onabotulinumtoxin A in 30
      ml NaCl 0.9 % or placebo with 30 ml NaCl 0.9 %. Bladder biopsies will be obtained in the
      same procedure. The treatment will be repeated after three months. All included patients
      will be evaluated with urodynamic examinations. Follow-up is 12 months after the first
      treatment. The primary endpoint of the study is development of NDO.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Presence of neurogenic detrusor overactivity  during cystometry, defined as contractions with amplitudes above 40 cm H2O.</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Urodynamic parameters</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Maximal detrusor pressure (cmH2O), maximal bladder capacity (ml), compliance (ΔcmH2O/Δml), and occurrence of DSD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (QOL) in the treated group compared to the placebo group 12 months after first treatment.</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of complications.</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Detrusor pathophysiology</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Differences in levels of transmitters and receptors relevant to development of bladder dysfunction, measured in urine samples and bladder biopsies, to gain knowledge of the pathophysiology behind neurogenic detrusor overactivity.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Spinal Cord Injuries</condition>
  <condition>Urinary Bladder, Overactive</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>30 transurethral injections, each of 1 ml solution containing NaCl.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Onabotulinumtoxin A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>30 transurethral injections, each of 1 ml solution containing 300 U Onabotulinumtoxin A (Botox ®, &quot;Allergan&quot;) in 30 ml of NaCl 0.9 %.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Onabotulinumtoxin A</intervention_name>
    <description>30 transurethral injections, each of 1 ml solution containing 300 U Onabotulinumtoxin A (Botox ®, &quot;Allergan&quot;) in 30 ml of NaCl 0.9 %.</description>
    <arm_group_label>Onabotulinumtoxin A</arm_group_label>
    <other_name>Botox ®, &quot;Allergan&quot;</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>30 transurethral injections, each of 1 ml solution containing NaCl.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>NaCl</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with documented acute, motor complete C6 to Th11 spinal cord injury

          -  Patients can be included in the study less than four weeks after injury

          -  Male or female, aged 18 to 80 years old

          -  Patient weight &gt; 40 kg

          -  Patient is able and willing to sign informed consent

          -  Patient is able to complete all study requirements

        Exclusion Criteria:

          -  Neurogenic detrusor overactivity with contractions greater than 40 cm H2O at first
             visit

          -  History or evidence of previous urological abnormalities, disease or surgery, except
             bladder dysfunction after spinal cord injury

          -  History of haematuria or ongoing haematuria, if the hematuria is determined to be a
             pathologic condition or is uninvestigated

          -  Pregnancy or females of childbearing potential unwilling to use a reliable form of
             contraception

          -  Breastfeeding

          -  Known allergy to Onabotulinumtoxin A

          -  Grave psychiatric disorder

          -  Use of anti-platelet or anti-coagulant other than low molecular weight heparin (LMWH)
             or acetylsalicylic acid

          -  Haemophilia or other clotting disorders that cause bleeding diathesis

          -  Treatment with antimuscarinic medication within 3 months of randomization

          -  Treatment with botulinum toxin of any serotype within 3 months of randomization

          -  Patient has been immunized for any botulinum toxin serotype

          -  Patient has any medical condition that may put the patient at increased risk with
             exposure to botulinum toxin including diagnosed myasthenia gravis, Eaton-Lambert
             syndrome or amyotrophic lateral sclerosis

          -  Patient has any condition or situation, which, in the investigator's opinion, puts
             the patient at significant risk, could confound the study results, or may interfere
             significantly with the patient's participation in the study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lars Frich, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oslo, Norway</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ole Jacob Nilsen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oslo, Norway</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas Glott, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sunnaas Rehabilitation Hospital, Norway</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ole Jacob Nilsen, MD.</last_name>
    <phone>+47 23070000</phone>
    <email>ojnilsen@ous-hf.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Thomas Glott, MD.</last_name>
    <phone>+47 66969000</phone>
    <email>thomas.glott@sunnaas.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sunnaas Hospital</name>
      <address>
        <city>Nesoddtangen</city>
        <zip>1450</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Glott, MD.</last_name>
      <phone>+47 66969000</phone>
      <email>thomas.glott@sunnaas.no</email>
    </contact>
    <investigator>
      <last_name>Thomas Glott, MD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>0027</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ole Jacob Nilsen, MD.</last_name>
      <phone>+47 23070000</phone>
      <email>ojnilsen@ous-hf.no</email>
    </contact>
    <contact_backup>
      <last_name>Lars Frich, MD. PhD.</last_name>
      <phone>+47 23070000</phone>
      <email>lfrich@ous-hf.no</email>
    </contact_backup>
    <investigator>
      <last_name>Lars Frich, MD, PhD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ole Jacob Nilsen, MD.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 15, 2014</lastchanged_date>
  <firstreceived_date>September 26, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Lars Frich</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Spinal cord injury</keyword>
  <keyword>Neurogenic overactive bladder</keyword>
  <keyword>Onabotulinum toxin A</keyword>
  <keyword>Prevention</keyword>
  <keyword>Botulinum Toxins, Type A</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Spinal Cord Injuries</mesh_term>
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
